Dipti Thakkar

Dipti Thakkar is the Vice President of the Target Biology and Pharmacology group at Hummingbird Bioscience. She leads the company’s pre-clinical pharmacology and toxicology programs in collaboration with internal and external partners.

As a molecular biologist by training, she has garnered over 12 years of experience developing disease-relevant assay models to support in vivo/in vitro efficacy and safety assessment for disease therapeutics. Dipti’s work has led her to be shortlisted by the prestigious Society for Immunotherapy of Cancer from a global search, as one of 29 young lead investigators, to address obstacles in the field of cancer immunotherapy in 2018.

In her previous academic roles at University of Oxford and National Neuroscience Institute, she worked extensively towards understanding patient heterogeneity and identifying gene signatures for patient stratification. She plays a pivotal role in the development of Hummingbird’s two lead assets from discovery to IND filing.